相关实验视频

Updated: Jul 27, 2025

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

通过单克隆抗体疗法产生SARS-CoV-2逃生突变

Manon Ragonnet-Cronin^1,2, Rungtiwa Nutalai³, Jiandong Huo⁴

¹Genomics Public Health Analysis, UK Health Security Agency, London, UK. manonragonnet@uchicago.edu.

Nature communications

|June 7, 2023

概括

新出现的SARS-CoV-2突变可能导致对COVID-19治疗的耐药性,例如单克隆抗体 (mAbs). 这项研究表明,特定突变降低了抗体的有效性,影响了治疗疗效和潜在的疫苗反应.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

中和单克隆抗体 (mAbs) 对于治疗高危COVID-19患者至关重要.
用组合的mAbs或向保护区域的管理旨在防止病毒逃逸.

研究的目的:

检测和描述新出现的SARS-CoV-2对特定单克隆抗体 (mAbs) 的耐药性突变.
评估这些突变对抗体结合,中和活性和疫苗诱导的血清活性的影响.

主要方法:

在英国利用了前所未有的SARS-CoV-2基因组监测.
采用了表面等离子体共振和伪病毒中和试验.
在Delta和Omicron变异中分析了抗体表位体内的突变.

主要成果:

在用casirivimab+imdevimab和sotrovimab治疗的SARS-CoV-2变体中,在抗体表位内发现了突变.
证明这些突变减少或取消抗体亲和力和中和活性.
观察到一些突变也降低了疫苗诱导血清的中和活性.

结论:

新出现的SARS-CoV-2突变是由免疫逃避驱动的,导致对单克隆抗体治疗产生抵抗力.
这些突变对mAb疗法的有效性构成重大挑战.
这些发现凸显了持续基因组监测的必要性,以监测和打击抗病毒药物耐药性.

更多相关视频

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...